CSF2 and neuroblastoma: A combination of IL-2, 13cRA, granulocyte-macrophage colony-stimulating factor (GM-CSF), and anti-GD2 antibody was approved as a therapy for neuroblastoma in 2010; however, no data about the influence of this treatment on patients' NK cells were presented [25].